<p>Toth Financial Advisory Corp 在最近向证券交易委员会提交的 13F 表格中表示，在第三季度将其在强生（NYSE:JNJ - 免费报告）股票中的持股比例提高了 8.6%。该公司在此期间购买了额外的 5,664 股后，持有该公司 71,201 股股票。强生在 Toth Financial Advisory Corp 的投资组合中占约 1.4%，使其成为该公司第 17 大持股。根据其最近向证券交易委员会提交的文件，Toth Financial Advisory Corp 在强生的持股价值为 13,202,000 美元。</p>
<p>获取 <strong>强生</strong> 的提醒：</p>
<ul>
<li>降息使这三只收益 ETF 比以往更具吸引力</li>
</ul>
<p>其他几家大型投资者最近也对 JNJ 的持仓进行了调整。挪威银行在第二季度购买了价值约 4,877,174,000 美元的强生新股份。Laurel Wealth Advisors LLC 在第二季度将其在强生的持股比例提高了 15,040.6%。Laurel Wealth Advisors LLC 现在拥有 7,420,699 股该公司的股票，价值 1,133,512,000 美元，此前在上个季度购买了额外的 7,371,687 股。先锋集团在第二季度将其在强生的持股比例提高了 1.3%。先锋集团现在拥有 237,047,859 股该公司的股票，价值 36,209,060,000 美元，此前在上个季度又收购了 3,085,180 股。Assenagon Asset Management S.A. 在第二季度将其在强生的持股比例提高了 159.6%。Assenagon Asset Management S.A. 现在拥有 4,159,260 股该公司的股票，价值 635,327,000 美元，此前在上个季度又收购了 2,557,388 股。最后，Kingstone Capital Partners Texas LLC 在第二季度收购了价值约 401,420,000 美元的强生新股份。69.55% 的股票由机构投资者持有。</p>
<h2>强生新闻摘要</h2>
<p>以下是本周影响强生的主要新闻：</p>
<ul>
<li>积极情绪：FDA 批准了 Rybrevant（amivantamab）的皮下版本，将 EGFR 突变的非小细胞肺癌（NSCLC）给药时间从数小时缩短到数分钟——这大大提高了患者的便利性，可能提高与静脉治疗的使用率，并支持强生肺癌业务的长期收入潜力。强生获得 FDA 批准的非小细胞肺癌药物 Rybrevant 的皮下版本</li>
<li>积极情绪：FDA 批准 RYBREVANT FASPRO（amivantamab + 透明质酸酶）作为 Rybrevant 所有适应症的首个皮下治疗，结合 LAZCLUZE 时可实现更短、更简单的一线治疗方案——这一监管胜利支持商业使用和利润率。美国 FDA 批准 RYBREVANT FASPRO</li>
<li>积极情绪：强生的医疗科技部门获得 FDA 批准 TRUFILL n-BCA 液体栓塞系统，用于治疗症状性慢性硬膜下血肿（cSDH），扩展神经血管适应症并支持设备收入增长。强生获得 FDA 批准的 TRUFILL n-BCA</li>
<li>积极情绪：媒体和投资者情绪乐观：吉姆·克莱默强调了强生在肿瘤学领域的势头以及对医疗保健/防御性股票的更广泛轮动，这可能推动零售兴趣并支持估值扩张。吉姆·克莱默对强生（JNJ）的癌症药物赞不绝口</li>
<li>中性情绪：分析师/估值评论认为，强生的溢价倍数得益于加速增长和投资组合组合；这是长期定位的有用背景，但不太可能在短期内推动价格。强生：加速增长证明了估值溢价的合理性</li>
<li>中性情绪：宏观说明：降息和对高质量分红支付者（如强生）的 ETF 流入（例如，在 MarketBeat 文章中的提及）可以支持需求，但影响是渐进的。降息使这三只收益 ETF 比以往更具吸引力</li>
<li>消极情绪：短期内的回调可能是由于在大幅上涨后的获利了结（股票年初至今大幅上涨）；尽管有积极的催化剂，但大量交易表明短期内存在卖压。</li>
</ul>
<h2>分析师设定新目标价</h2>
<ul>
<li>辉瑞加大对减肥药的投资</li>
</ul>
<p>几家券商最近对强生发表了评论。BMO Capital Markets 在 12 月 11 日的报告中重申了对强生股票的 “跑赢大盘” 评级。Johnson Rice 在 10 月 22 日的研究报告中将强生的目标价设定为 190.00 美元，并给予该公司 “持有” 评级。大和美国在 10 月 20 日的报告中将强生的评级从 “持有” 上调至 “强力买入”。花旗集团在 12 月 11 日的研究报告中将强生的目标价从 215.00 美元提高至 232.00 美元，并给予该股票 “买入” 评级。最后，美国银行在 12 月 15 日的研究报告中将强生股票的目标价从 204.00 美元提高至 220.00 美元，并给予该股票 “中性” 评级。四位股票研究分析师对该股票给予了强力买入评级，十四位给予了买入评级，九位给予了持有评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价为 210.25 美元。</p>
<p><strong>获取我们最新的 JNJ 股票报告</strong></p>
<h2>强生股票下跌 0.9%</h2>
<ul>
<li>5 家医疗保健公司值得关注，因为行业轮动正在全面展开</li>
</ul>
<p>强生（NYSE:JNJ）股票周五开盘价为 206.49 美元。该公司的速动比率为 0.80，流动比率为 1.07，债务与股本比率为 0.50。强生的 52 周低点为 140.68 美元，52 周高点为 215.18 美元。该股票的市值为 4974.9 亿美元，市盈率为 19.93，PEG 比率为 2.24，贝塔系数为 0.36。该公司的 50 日移动平均价格为 198.10 美元，200 日移动平均价格为 179.19 美元。</p>
<p>强生公司（NYSE:JNJ - 获取免费报告）最近在 8 月 30 日（星期三）发布了其财报。该公司报告本季度每股收益为 2.26 美元。强生公司的股本回报率为 32.73%，净利润率为 27.26%。该公司本季度的收入为 240.2 亿美元。股票分析师预测，强生公司在当前年度将发布每股收益 10.58 美元。</p>
<h2>强生公司宣布分红</h2>
<p>该公司最近还披露了季度分红，分红于 12 月 9 日（星期二）支付。11 月 25 日（星期二）登记在册的股东获得了 1.30 美元的分红。除息日期为 11 月 25 日（星期二）。这相当于每年 5.20 美元的分红，分红收益率为 2.5%。强生公司的分红支付比率目前为 50.19%。</p>
<h2>强生公司简介</h2>
<p>（免费报告）</p>
<p>强生是一家总部位于新泽西州新布伦瑞克的跨国医疗保健公司，开发、制造和销售广泛的产品，涵盖制药、医疗设备以及以前的消费者健康产品。该公司由约翰逊家族于 1886 年创立，已发展成为一个在全球多个国家开展业务和销售的全球医疗保健组织。</p>
<p>该公司的制药业务主要在其扬森研究与开发组织下运作，专注于免疫学、传染病、肿瘤学和神经科学等治疗领域的处方药。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过强生</li>
<li>如何购买黄金股票并投资黄金</li>
<li>这三家银行在年末反弹，但这种趋势会持续吗？</li>
<li>现在购买的三只最佳蓝筹股</li>
<li>三只飙升的股票刚刚获得标准普尔 500 的最终认可</li>
<li>关注国会股票交易</li>
<li>这只 ETF 在美联储降息后获得了重大助力</li>
</ul>
<p><strong>想看看其他对 JNJ 感兴趣的对冲基金吗？</strong> 访问 HoldingsChannel.com，获取强生公司（NYSE:JNJ - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在强生公司吗？</h2>
<p>在考虑强生公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而强生公司并不在名单上。</p>
<p>虽然强生公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

强生

<p>Toth Financial Advisory Corp 在第三季度将其在强生的股份增加了 8.6%，目前持有 71,201 股，价值 13,202,000 美元。其他投资者如挪威银行和先锋集团也调整了他们在强生的持仓。由于 FDA 的批准和乐观的媒体报道，市场对强生的情绪积极，而分析师们设定了新的价格目标，反映出对该股票未来表现的看法存在分歧</p>

<p>Toth Financial Advisory Corp boosted its stake in shares of Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 8.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm owned 71,201 shares of the company's stock after buying an additional 5,664 shares during the period. Johnson &amp; Johnson accounts for about 1.4% of Toth Financial Advisory Corp's investment portfolio, making the stock its 17th biggest holding. Toth Financial Advisory Corp's holdings in Johnson &amp; Johnson were worth $13,202,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>Toth Financial Advisory Corp 在最近向证券交易委员会提交的 13F 表格中表示，在第三季度将其在强生（NYSE:JNJ - 免费报告）股票中的持股比例提高了 8.6%。该公司在此期间购买了额外的 5,664 股后，持有该公司 71,201 股股票。强生在 Toth Financial Advisory Corp 的投资组合中占约 1.4%，使其成为该公司第 17 大持股。根据其最近向证券交易委员会提交的文件，Toth Financial Advisory Corp 在强生的持股价值为 13,202,000 美元。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>强生</strong> 的提醒：</p>
</div><ul>
<li>Rate Cuts Make These 3 Income ETFs More Attractive Than Ever</li>
</ul>
<div class="lb-trans"><ul>
<li>降息使这三只收益 ETF 比以往更具吸引力</li>
</ul>
</div><p>Several other large investors have also recently made changes to their positions in JNJ. Norges Bank purchased a new position in Johnson &amp; Johnson in the second quarter valued at about $4,877,174,000. Laurel Wealth Advisors LLC grew its position in shares of Johnson &amp; Johnson by 15,040.6% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company's stock worth $1,133,512,000 after buying an additional 7,371,687 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Johnson &amp; Johnson by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company's stock worth $36,209,060,000 after acquiring an additional 3,085,180 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in Johnson &amp; Johnson by 159.6% during the second quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company's stock valued at $635,327,000 after acquiring an additional 2,557,388 shares during the last quarter. Finally, Kingstone Capital Partners Texas LLC acquired a new stake in Johnson &amp; Johnson in the second quarter valued at approximately $401,420,000. 69.55% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家大型投资者最近也对 JNJ 的持仓进行了调整。挪威银行在第二季度购买了价值约 4,877,174,000 美元的强生新股份。Laurel Wealth Advisors LLC 在第二季度将其在强生的持股比例提高了 15,040.6%。Laurel Wealth Advisors LLC 现在拥有 7,420,699 股该公司的股票，价值 1,133,512,000 美元，此前在上个季度购买了额外的 7,371,687 股。先锋集团在第二季度将其在强生的持股比例提高了 1.3%。先锋集团现在拥有 237,047,859 股该公司的股票，价值 36,209,060,000 美元，此前在上个季度又收购了 3,085,180 股。Assenagon Asset Management S.A. 在第二季度将其在强生的持股比例提高了 159.6%。Assenagon Asset Management S.A. 现在拥有 4,159,260 股该公司的股票，价值 635,327,000 美元，此前在上个季度又收购了 2,557,388 股。最后，Kingstone Capital Partners Texas LLC 在第二季度收购了价值约 401,420,000 美元的强生新股份。69.55% 的股票由机构投资者持有。</p>
</div><h2>Johnson &amp; Johnson News Summary</h2>
<div class="lb-trans"><h2>强生新闻摘要</h2>
</div><p>Here are the key news stories impacting Johnson &amp; Johnson this week:</p>
<div class="lb-trans"><p>以下是本周影响强生的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: FDA approves a subcutaneous version of Rybrevant (amivantamab) that reduces administration time from hours to minutes for EGFR‑mutated NSCLC — this materially improves patient convenience, may raise uptake vs. IV therapy and supports long‑term revenue potential for JNJ’s lung‑cancer franchise. J&amp;J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant</li>
<li>Positive Sentiment: FDA clears RYBREVANT FASPRO (amivantamab + hyaluronidase) as the first subcutaneous therapy across Rybrevant indications, enabling much shorter, simpler first‑line regimens when combined with LAZCLUZE — a regulatory win that supports commercial uptake and margins. U.S. FDA Approval of RYBREVANT FASPRO</li>
<li>Positive Sentiment: JNJ’s MedTech unit won FDA clearance for the TRUFILL n‑BCA liquid embolic system to treat symptomatic chronic subdural hematoma (cSDH), expanding neurovascular indications and supporting device revenue growth. Johnson &amp; Johnson Receives FDA Approval for TRUFILL n‑BCA</li>
<li>Positive Sentiment: Media and investor sentiment is bullish: Jim Cramer highlighted JNJ’s oncology momentum and broader rotation into healthcare/defensive names, which can drive retail interest and support multiple expansion. Jim Cramer Couldn’t Stop Gushing About Johnson &amp; Johnson (JNJ)’s Cancer Drugs</li>
<li>Neutral Sentiment: Analyst/valuation commentary argues JNJ’s premium multiple is supported by accelerating growth and portfolio mix; useful context for longer‑term positioning but less likely to move near‑term price. Johnson and Johnson: Valuation Premium Justified By Accelerating Growth</li>
<li>Neutral Sentiment: Macro note: rate cuts and dividend‑friendly ETF flows (e.g., mentions in MarketBeat pieces) can support demand for high‑quality dividend payers like JNJ, but impact is gradual. Rate Cuts Make These 3 Income ETFs More Attractive Than Ever</li>
<li>Negative Sentiment: Near‑term pullback likely driven by profit‑taking after a large YTD move (shares are up significantly year‑to‑date); heavy volume suggests short‑term selling pressure despite positive catalysts.</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：FDA 批准了 Rybrevant（amivantamab）的皮下版本，将 EGFR 突变的非小细胞肺癌（NSCLC）给药时间从数小时缩短到数分钟——这大大提高了患者的便利性，可能提高与静脉治疗的使用率，并支持强生肺癌业务的长期收入潜力。强生获得 FDA 批准的非小细胞肺癌药物 Rybrevant 的皮下版本</li>
<li>积极情绪：FDA 批准 RYBREVANT FASPRO（amivantamab + 透明质酸酶）作为 Rybrevant 所有适应症的首个皮下治疗，结合 LAZCLUZE 时可实现更短、更简单的一线治疗方案——这一监管胜利支持商业使用和利润率。美国 FDA 批准 RYBREVANT FASPRO</li>
<li>积极情绪：强生的医疗科技部门获得 FDA 批准 TRUFILL n-BCA 液体栓塞系统，用于治疗症状性慢性硬膜下血肿（cSDH），扩展神经血管适应症并支持设备收入增长。强生获得 FDA 批准的 TRUFILL n-BCA</li>
<li>积极情绪：媒体和投资者情绪乐观：吉姆·克莱默强调了强生在肿瘤学领域的势头以及对医疗保健/防御性股票的更广泛轮动，这可能推动零售兴趣并支持估值扩张。吉姆·克莱默对强生（JNJ）的癌症药物赞不绝口</li>
<li>中性情绪：分析师/估值评论认为，强生的溢价倍数得益于加速增长和投资组合组合；这是长期定位的有用背景，但不太可能在短期内推动价格。强生：加速增长证明了估值溢价的合理性</li>
<li>中性情绪：宏观说明：降息和对高质量分红支付者（如强生）的 ETF 流入（例如，在 MarketBeat 文章中的提及）可以支持需求，但影响是渐进的。降息使这三只收益 ETF 比以往更具吸引力</li>
<li>消极情绪：短期内的回调可能是由于在大幅上涨后的获利了结（股票年初至今大幅上涨）；尽管有积极的催化剂，但大量交易表明短期内存在卖压。</li>
</ul>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞加大对减肥药的投资</li>
</ul>
</div><p>Several brokerages have recently commented on JNJ. BMO Capital Markets reiterated an &#34;outperform&#34; rating on shares of Johnson &amp; Johnson in a report on Thursday, December 11th. Johnson Rice set a $190.00 target price on Johnson &amp; Johnson and gave the company a &#34;hold&#34; rating in a research report on Wednesday, October 22nd. Daiwa America raised Johnson &amp; Johnson from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Monday, October 20th. Citigroup boosted their price target on Johnson &amp; Johnson from $215.00 to $232.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, December 11th. Finally, Bank of America lifted their target price on shares of Johnson &amp; Johnson from $204.00 to $220.00 and gave the stock a &#34;neutral&#34; rating in a research note on Monday, December 15th. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and an average price target of $210.25.</p>
<div class="lb-trans"><p>几家券商最近对强生发表了评论。BMO Capital Markets 在 12 月 11 日的报告中重申了对强生股票的 “跑赢大盘” 评级。Johnson Rice 在 10 月 22 日的研究报告中将强生的目标价设定为 190.00 美元，并给予该公司 “持有” 评级。大和美国在 10 月 20 日的报告中将强生的评级从 “持有” 上调至 “强力买入”。花旗集团在 12 月 11 日的研究报告中将强生的目标价从 215.00 美元提高至 232.00 美元，并给予该股票 “买入” 评级。最后，美国银行在 12 月 15 日的研究报告中将强生股票的目标价从 204.00 美元提高至 220.00 美元，并给予该股票 “中性” 评级。四位股票研究分析师对该股票给予了强力买入评级，十四位给予了买入评级，九位给予了持有评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价为 210.25 美元。</p>
</div><p><strong>Get Our Latest Stock Report on JNJ</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 JNJ 股票报告</strong></p>
</div><h2>Johnson &amp; Johnson Trading Down 0.9%</h2>
<div class="lb-trans"><h2>强生股票下跌 0.9%</h2>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 家医疗保健公司值得关注，因为行业轮动正在全面展开</li>
</ul>
</div><p>Shares of NYSE:JNJ opened at $206.49 on Friday. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. Johnson &amp; Johnson has a 52-week low of $140.68 and a 52-week high of $215.18. The stock has a market cap of $497.49 billion, a price-to-earnings ratio of 19.93, a PEG ratio of 2.24 and a beta of 0.36. The business has a 50-day moving average price of $198.10 and a 200-day moving average price of $179.19.</p>
<div class="lb-trans"><p>强生（NYSE:JNJ）股票周五开盘价为 206.49 美元。该公司的速动比率为 0.80，流动比率为 1.07，债务与股本比率为 0.50。强生的 52 周低点为 140.68 美元，52 周高点为 215.18 美元。该股票的市值为 4974.9 亿美元，市盈率为 19.93，PEG 比率为 2.24，贝塔系数为 0.36。该公司的 50 日移动平均价格为 198.10 美元，200 日移动平均价格为 179.19 美元。</p>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson &amp; Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion for the quarter. Equities analysts predict that Johnson &amp; Johnson will post 10.58 EPS for the current year.</p>
<div class="lb-trans"><p>强生公司（NYSE:JNJ - 获取免费报告）最近在 8 月 30 日（星期三）发布了其财报。该公司报告本季度每股收益为 2.26 美元。强生公司的股本回报率为 32.73%，净利润率为 27.26%。该公司本季度的收入为 240.2 亿美元。股票分析师预测，强生公司在当前年度将发布每股收益 10.58 美元。</p>
</div><h2>Johnson &amp; Johnson Announces Dividend</h2>
<div class="lb-trans"><h2>强生公司宣布分红</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were paid a $1.30 dividend. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. Johnson &amp; Johnson's dividend payout ratio is presently 50.19%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，分红于 12 月 9 日（星期二）支付。11 月 25 日（星期二）登记在册的股东获得了 1.30 美元的分红。除息日期为 11 月 25 日（星期二）。这相当于每年 5.20 美元的分红，分红收益率为 2.5%。强生公司的分红支付比率目前为 50.19%。</p>
</div><h2>Johnson &amp; Johnson Company Profile</h2>
<div class="lb-trans"><h2>强生公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Johnson &amp; Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.</p>
<div class="lb-trans"><p>强生是一家总部位于新泽西州新布伦瑞克的跨国医疗保健公司，开发、制造和销售广泛的产品，涵盖制药、医疗设备以及以前的消费者健康产品。该公司由约翰逊家族于 1886 年创立，已发展成为一个在全球多个国家开展业务和销售的全球医疗保健组织。</p>
</div><p>The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.</p>
<div class="lb-trans"><p>该公司的制药业务主要在其扬森研究与开发组织下运作，专注于免疫学、传染病、肿瘤学和神经科学等治疗领域的处方药。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>How to Buy Gold Stock and Invest in Gold</li>
<li>These 3 Banks Are Rallying Into Year-End, But Will It Continue?</li>
<li>The 3 Best Blue-Chip Stocks to Buy Now</li>
<li>3 Surging Stocks Just Got the Ultimate Stamp of Approval From the S&amp;P 500</li>
<li>Following Congress Stock Trades</li>
<li>This ETF Caught a Major Tailwind After the Fed’s Rate Cut</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过强生</li>
<li>如何购买黄金股票并投资黄金</li>
<li>这三家银行在年末反弹，但这种趋势会持续吗？</li>
<li>现在购买的三只最佳蓝筹股</li>
<li>三只飙升的股票刚刚获得标准普尔 500 的最终认可</li>
<li>关注国会股票交易</li>
<li>这只 ETF 在美联储降息后获得了重大助力</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding JNJ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 JNJ 感兴趣的对冲基金吗？</strong> 访问 HoldingsChannel.com，获取强生公司（NYSE:JNJ - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在强生公司吗？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑强生公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而强生公司并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然强生公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Toth Financial Advisory Corp 增加了对强生公司$JNJ 的持股